Table 2. Treatment pattern and responses in patients with MM (n = 68).
| Initial treatment given VTD CYBORD RD MPV |
Group 1 (30–40 years) 4 (44.4) 4 (44.5) 1 (11.1) 0 (0.0) |
Group 2 (41–50 years) 10 (33.3) 12 (40.0) 8 (26.7) 0 (0.0) |
Group 3 (51–55 years) 14 (48.3) 4 (13.8) 10 (34.5) 1 (3.4) |
p-value 0.18 |
|---|---|---|---|---|
|
Number of chemotherapy cycles Median |
4 |
4 |
4 |
|
|
Treatment response after induction PR VGPR CR sCR |
7 (77.8) 0 (0.0) 0 (0.0) 0 (0.0) |
16 (53.3) 3 (10.0) 2 (6.7) 2 (6.7) |
16 (55.2) 5 (17.2) 5 (17.2) 1 (3.5) |
0.987 |
| PD | 2(22.2) | 7(23.3) | 2(6.9) | |
|
Autologous transplant No/NA Yes |
7 (77.8) 2 (22.2) |
27 (90.0) 3 (10.0) |
28 (96.5) 1 (3.5) |
0.27 |
|
Maintenance therapy given Yes No/NA |
8 (88.8) 1 (11.1) |
22 (73.3) 8 (26.6) |
25 (86.2) 4 (13.8) |
0.782 |
|
Type of maintenance therapy LEN/DEX THAL/DEX |
3 (33.3) 3 (33.3) |
12 (40.0) 8 (26.6) |
13 (44.8) 11 (37.9) |
0.985 |
| LEN | 2(22.2) | 1(3.3) | 1(3.4) | |
| BOR | 0(0) | 1(3.3) | 0(0) | |
|
Lines of treatment <3 3 |
5 (55.6) 4 (44.4) |
18 (60.0) 12 (40.0) |
18 (62.1) 11 (37.9) |
0.71 |
Velcade, Thalidomide, Dexamethasone (VTD), CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Lenalidomide, Dexamethasone (RD), Melphalan, Prednisone, Velcade (MPV), CR: Complete Response, VGPR: Very Good Partial Response, PR: Partial Response, sCR: Stringent Complete Response PD Progressive Disease